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Abstract
The natural history of infections with many human papillomavirus (HPV) types is poorly understood. Here, we describe for the
first time the age- and sex-dependent antibody prevalence for 29 cutaneous and five mucosal HPV types from 15 species
within five phylogenetic genera (alpha, beta, gamma, mu, nu) in a general population. Sera from 1,797 German adults and
children (758 males and 1,039 females) between 1 and 82 years (median 37 years) were analysed for antibodies to the major
capsid protein L1 by Luminex-based multiplex serology. The first substantial HPV antibody reactions observed already in
children and young adults are those to cutaneous types of the genera nu (HPV 41) and mu (HPV 1, 63). The antibody
prevalence to mucosal high-risk types, most prominently HPV 16, was elevated after puberty in women but not in men and
peaked between 25 and 34 years. Antibodies to beta and gamma papillomaviruses (PV) were rare in children and increased
homogeneously with age, with prevalence peaks at 40 and 60 years in women and 50 and 70 years in men. Antibodies to
cutaneous alpha PV showed a heterogeneous age distribution. In summary, these data suggest three major seroprevalence
patterns for HPV of phylogenetically distinct genera: antibodies to mu and nu skin PV appear early in life, those to mucosal
alpha PV in women after puberty, and antibodies to beta as well as to gamma skin PV accumulate later in life.
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Introduction
Papillomaviruses (PV) are non-enveloped DNA viruses infecting
cutaneous or mucosal epithelia of warm-blooded vertebrates. So
far at least 118 distinct PV types, more than 100 of them isolated
from humans, have been completely described [1]. In addition,
about 130 L1 sequence fragments have been isolated by means of
a broad spectrum polymerase chain reaction (PCR) representing
putatively new cutaneous human papillomavirus (HPV) types [2].
Based on the nucleotide sequence encoding the major capsid
protein L1, PV systematics defines 16 genera (sharing less than
60% sequence identity) which encompass 44 species (sharing 60–
70% sequence identity).
PV within the same genus may or may not show similar
biological and pathological characteristics. Thus, cutaneous HPV
are found among the five genera alpha (species 2, 4 and 8), beta
(b), gamma (c), mu (m), and nu (n), whereas the 48 HPV types
infecting the mucosa belong exclusively to the genus alpha (a).
HPV infections are widespread and can cause a variety of mostly
benign tumours such as warts and condylomata. However, the
infection with certain mucosal HPV types leads to malignant cell
proliferation [3]. Fifteen so-called high-risk (HR) and three
putative HR mucosal HPV of genus a, most notably the two
most prevalent HR types 16 and 18, are found in more than 90%
of cervical tumours [4] and with lower frequency in other
anogenital and oro-pharyngeal carcinomas [3]. Thirteen of these
HPV types have recently been classified as human carcinogens [5].
The mucosal low-risk (LR) HPV types 6 and 11 cause benign
genital lesions like condylomata acuminata and low-grade
squamous intraepithelial lesions of the cervix. The cutaneous
HPV types 1 (genus m), 2, 3, 10, 57 (genus a) and HPV 4 (genus c),
although belonging to three different genera, are associated with
benign plantar, common, and flat skin warts both in the general
population and in renal transplant recipients [6,7]. b PV are found
in high copy numbers in benign macular skin lesions of patients
with the rare hereditary disease Epidermodysplasia verruciformis
(EV) [8]. The same types are also found in non-melanoma skin
cancer (NMSC), namely squamous cell carcinoma (SCC) and less
frequently basal cell carcinoma (BCC) of the skin, but also in
normal skin and plucked hairs of EV patients, immunosuppressed
patients, e.g. transplant recipients, and less frequently immuno-
competent patients [9,10]. c PV and HPV 41 (genus n) cause
PLoS Pathogens | www.plospathogens.org 1 June 2008 | Volume 4 | Issue 6 | e1000091benign skin lesions but have been also found in NMSC
[1,3,11,12]. Thus, infections with cutaneous HPV are discussed
to play a role in the development of NMSC [9,10].
Besides the extensively studied HPV 16 and some closely related
mucosal HR types, only little is known about the natural history of
infections by other types. For both HR (e.g. HPV 16, 18, 31, 33,
35, 45, 52, 58) and LR (e.g. HPV 6 and 11) mucosal HPV,
transmission occurs mainly via sexual intercourse [13]. However,
non-sexual routes of transmission, e.g. oral and perinatal
transmission have been reported and cannot be entirely disre-
garded [14,15]. The rare disease recurrent respiratory papilloma-
tosis apparently is caused by perinatal transmission of the LR HPV
types 6 and 11 [16]. Infections with cutaneous HPV are assumed
to occur via skin contact with contaminated material.
For mucosal HPV types, antibodies to the viral major capsid
protein L1 have been shown to be markers for present and past
infection. Thus serology provides a powerful epidemiological tool
to investigate the wide variety of mucosal and cutaneous HPV
types and their distribution in the population [17]. DNA detection
methods identify only current infections and are restricted to small
samples of certain bodily sites. In contrast, for HPV 16 it has been
shown that serology may be used as a proxy for lifetime cumulative
exposure [17]. However, only 50–60% of HPV 16 DNA positive
women develop HPV antibodies and seroconversion can occur
even several months after the infection [17,18]. HPV 16 L1
antibodies have low but stable titres and can be detected decades
after the infection [17]. Antibodies to HPV 16 L1 have been
shown to be type-specific [17,18], although some cross-reactivity
with closely related types was reported [18,19]. For the other HPV
types, similar characteristics of L1 antibodies are assumed.
Seroepidemiological studies especially on cutaneous HPV
infection are scarce and those performed in the past were
restricted to a single or few HPV types. To our knowledge,
mucosal HPV L1 antibody analyses have been performed so far
for HR HPV types 16, 18, 31, 33, 39, 45, 52, 58, 59, 73, for LR
HPV types 6 and 11 and for HPV types 13 and 32. The
serologically best studied cutaneous types are HPV 1, 5, and 8
[20–37], while little or nothing is known about the antibody
response to other cutaneous types [38–45].
HPV antibody analyses are complex because of the large
number of HPV types, and conventional enzyme-linked immu-
nosorbent assay (ELISA) methods allow analysing the reactivity of
a serum sample to only one antigen per reaction. We recently
developed multiplex serology [46,47] that allows the simultaneous
determination of antibodies to a large number of HPV types and
the analysis of more than 1,000 sera per day. Multiplex serology
uses viral L1 proteins expressed in bacteria as glutathione S-
transferase (GST) fusion proteins as antigens [48,49]. Rizk et al.
[50] demonstrated that these recombinant L1 proteins display
conformational epitopes. Three first case-control studies on
NMSC investigating the antibody response to a total of 16 [39],
31 [45], and 38 [44] different HPV types have been reported.
However, our knowledge about the natural history of HPV
infections is still limited.
Here we describe for the first time the age- and sex-dependent
antibody prevalence for 29 cutaneous and five mucosal HPV types
representing 15 species within five phylogenetic genera (a, b, c, m,
n) in a general population.
Results
HPV antibody reactivity patterns
To obtain an unbiased (cut-off free) impression of HPV
antibodies, the strength of the antibody reactions was plotted
against the percentile for each HPV type and age and sex group.
Figure 1 shows the plots for HPV types 1, 16 and 8, which are
representative for the three major antibody patterns found among
the 34 types analysed.
For all HPV types and in both sexes, antibody reactivity was
lowest in children. The biggest difference in antibody reactivity
was observed between children and young adults (15–24 years)
against HPV 1, which is representative for the HPV types within
the m and n genera. HPV 1 antibody reactivities were similar in
adults aged 25–54 years and gradually declined thereafter.
Antibody levels against HPV 16, which is representative for
genital/mucosal HPV types within the a PV, changed with age in
women but hardly in men. In comparison to children, antibody
reactivities were substantially higher in young women and peaked
in the 25–34 years age group.
Antibody reactivity to HPV 8, which is representative for HPV
types within the b and c PV, became stronger with age in both
genders. A first peak in antibody reactivity was observed in women
at about 40 years and in men at about 50 years. Especially among
men, a second peak was found in the oldest age group.
These age-dependent antibody patterns were present for both
strong and weak responses, down to reactions as low as 50 median
fluorescence intensities (MFI).
HPV antibody prevalence
The analysis of the complex antibody patterns was simplified by
the generation of seroprevalence values. HPV seroprevalence is
defined here for all HPV types and age and sex strata as percent of
sera reacting with a given HPV type above a cut-off value of 200
MFI.
In all 1797 sera, the overall seroprevalence for any of the 34
HPV types analysed was 59.7% (Table 1). However, the overall
type-specific seroprevalences strongly depended on age and sex.
HPV types 1 and 4 showed the highest type-specific
seroprevalences (17.0 and 16.9%, respectively) (Table 1). Among
children, HPV antibody prevalences were mostly low, with the
highest seroprevalences for types 3 (8.6%), 1 (6.4%), and 4 (4.8%).
Among adults (individuals post-puberty, $15 years), seropreva-
lence was highest again for HPV types 4 (18.3%) and 1 (18.2%),
followed by types 8 (12.4%), 63 (11.5%), 65 (11.0%), and 49
(10.1%), and lowest (,1.5%) for types 52, 60 and 93.
Seroprevalence patterns were similar for m and n PV, for high-
risk mucosal a PV in females, and for b and c PV, respectively
(Figure 2). Most HPV showed two seroprevalence peaks. Age at
Author Summary
Papillomaviruses (PV) are a large and highly diverse group
of DNA viruses that infect cutaneous and mucosal epithelia
of warm-blooded vertebrates. Of the more than 100
identified human PV (HPV) types, many cause benign
lesions like warts and papillomas, and some also cervical,
other anogenital, and oral cancers. For most HPV,
transmission routes, pathogenesis, and time and duration
of infection are only poorly understood. In the German
general population, we investigated the prevalence of
antibodies to the capsid proteins of 34 HPV types
representative of all five PV genera (alpha, beta, gamma,
mu, and nu) that contain HPV. We provide evidence for
different age- and sex-dependent seroprevalence patterns
of phylogenetically related HPV: antibodies to cutaneous
mu and nu PV appear early in life, those to mucosal alpha
PV after puberty, and those to beta and gamma skin PV
accumulate in adulthood.
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genera, but the second prevalence peak rather uniformly occurred
at old age, in females at about 60 years and in males at above 64
years.
For statistical analysis of the age- and sex-dependent seroprev-
alence patterns, age groups were combined to increase statistical
power (Table 1). Highly significant seroprevalence increases
(p,0.0001) from children to younger adults (15–34 years) (but
not from younger to older adults .34 years) were seen for mucosal
a (HPV 16), c (HPV 4, 65) and both m PV (HPV 1, 63). In
contrast, none of the 15 b PV types showed highly significant
seroprevalence increases from children to younger adults, but 6
types from younger to older adults (HPV 49, 76, 75, 38, 17 and 8).
Multiple seropositivity (.3, .8 types) increased significantly (at
least p,0.05) from children to younger adults but also from
younger to older adults.
The strongest sex difference was observed for the mucosal high-
risk HPV type 16. Seroprevalence in younger women was 5.8-fold
and in older women still 2.4-fold higher than in men of the same
age. For two other mucosal high-risk types, seroprevalence was
also slightly elevated in younger women (HPV 18, 2.1-fold and
HPV 33, 1.6-fold), however without statistical significance.
Seroprevalence for cutaneous a, b and c PV tended to be higher
in younger women than in younger men (median 1.3-fold), but
HPV 2 was the only individual type for which this difference was
statistically significant. In contrast, women .34 years showed a
lower seroprevalence for these genera than men (median 0.8-fold),
with significant differences for the HPV types 75, 9, and 5.
Figure 1. Distribution of antibody reactivity for HPV types 1, 16 and 8 in the German population. Antibodies against HPV L1 proteins
were analysed in 1797 sera from the German general population and stratified by sex and age. The strength of the antibody reactions expressed as
median fluorescence intensity (MFI) on the y-axis is plotted against the percentile on the x-axis. Data points were connected by spline curves. Colour
code, age groups in years and size of the groups are indicated in the inserts. Dashed black lines indicate the cut-off of 200 MFI. The figure reads as
follows (upper left panel, HPV 1 antibodies among females): In the 45–54 years age group, approximately 40% showed antibody reactions above 50
MFI, approximately 30% above 100 MFI, and approximately 20% above 200 MFI. For all HPV types and in both genders antibody reactivity was lowest
in children. The biggest difference in antibody reactivity was observed between children and young adults (15–24 years) against HPV 1. In
comparison to children, antibody levels against HPV 16 were substantially higher in young women but not in men. Antibody reactivity to HPV 8
became stronger with age in both genders and peaked in women at about 40 years and in men at about 50 years. Especially among men, a second
peak was found in the oldest age group. These antibody patterns were present also for weak responses well below the chosen cut-off.
doi:10.1371/journal.ppat.1000091.g001
Seroprevalence of 34 HPV Types in Germany
PLoS Pathogens | www.plospathogens.org 3 June 2008 | Volume 4 | Issue 6 | e1000091T
a
b
l
e
1
.
T
y
p
e
-
s
p
e
c
i
f
i
c
a
g
e
-
a
n
d
s
e
x
-
s
t
r
a
t
i
f
i
e
d
H
P
V
a
n
t
i
b
o
d
y
p
r
e
v
a
l
e
n
c
e
i
n
t
h
e
G
e
r
m
a
n
p
o
p
u
l
a
t
i
o
n
.
s
e
r
o
p
o
s
i
t
i
v
i
t
y
(
%
)
a
d
u
l
t
s
c
h
i
l
d
r
e
n
1
–
1
4
y
e
a
r
s
a
l
l
a
d
u
l
t
s
1
5
–
3
4
y
e
a
r
s
(
y
o
u
n
g
a
d
u
l
t
s
)
.
3
4
y
e
a
r
s
(
o
l
d
e
r
a
d
u
l
t
s
)
w
h
o
l
e
s
t
u
d
y
c
h
i
l
d
r
e
n
m
f
f
/
m
y
o
u
n
g
a
d
u
l
t
s
m
f
f
/
m
o
l
d
e
r
a
d
u
l
t
s
m
f
f
/
m
c
h
i
l
d
r
e
n
v
s
y
o
u
n
g
a
d
u
l
t
s
y
o
u
n
g
a
d
u
l
t
s
v
s
o
l
d
e
r
a
d
u
l
t
s
s
e
r
o
p
o
s
i
t
i
v
e
f
o
r
n
=
1
7
9
7
n
=
1
8
7
n
=
9
2
n
=
9
5
p
r
e
v
.
r
a
t
i
o
a
n
=
1
6
1
0
n
=
6
1
2
n
=
2
4
6
n
=
3
6
6
p
r
e
v
.
r
a
t
i
o
n
=
9
9
8
n
=
4
2
0
n
=
5
7
8
p
r
e
v
.
r
a
t
i
o
p
b
p
a
n
y
H
P
V
(
n
=
3
4
)
5
9
.
7
3
5
.
3
3
4
.
8
3
5
.
8
1
.
0
6
2
.
5
5
9
.
8
5
7
.
7
6
2
.
0
1
.
1
6
3
.
3
6
3
.
8
6
3
.
8
1
.
0
*
*
*
*
a
n
y
c
u
t
.
(
n
=
2
9
)
5
5
.
5
3
2
.
1
2
9
.
3
3
4
.
7
1
.
2
5
8
.
3
5
4
.
7
5
4
.
9
5
4
.
6
1
.
0
6
0
.
4
6
2
.
6
5
8
.
8
0
.
9
*
*
*
*
*
a
n
y
m
u
c
.
(
n
=
5
)
1
4
.
5
4
.
8
7
.
6
2
.
1
0
.
3
1
5
.
6
1
5
.
2
1
1
2
1
1
.
9
*
*
1
2
.
9
1
2
.
4
1
6
.
4
1
.
3
*
*
*
*
n
u
m
b
e
r
o
f
t
y
p
e
s
0
4
0
.
3
6
4
.
7
6
5
.
2
6
4
.
2
1
.
0
3
7
.
5
4
0
.
2
4
2
.
3
3
8
.
0
0
.
9
3
6
.
7
3
6
.
2
3
6
.
2
1
.
0
*
*
*
*
1
2
4
.
5
2
4
.
1
2
2
.
8
2
5
.
3
1
.
1
2
4
.
5
2
7
.
0
2
7
.
6
2
6
.
0
0
.
9
2
3
.
1
2
2
.
1
2
4
.
0
1
.
1
2
1
1
.
5
4
.
8
6
.
5
3
.
2
0
.
5
1
2
.
3
1
1
.
6
1
1
.
4
1
2
.
0
1
.
1
1
2
.
4
1
2
.
9
1
2
.
5
1
.
0
*
*
3
7
.
4
4
.
3
3
.
3
5
.
3
1
.
6
7
.
8
7
.
5
5
.
7
9
.
3
1
.
6
7
.
9
7
.
4
8
.
0
1
.
1
.
3
1
6
.
2
2
.
1
2
.
2
2
.
1
1
.
0
1
7
.
9
1
3
.
7
1
3
.
0
1
4
.
8
1
.
1
1
9
.
8
2
1
.
4
1
9
.
4
0
.
9
*
*
*
*
*
*
.
8
6
.
1
0
.
5
1
.
1
0
.
0
0
.
0
6
.
7
4
.
2
3
.
3
5
.
2
1
.
6
7
.
9
1
0
.
0
6
.
7
0
.
7
*
*
*
.
1
6
1
.
9
0
.
0
0
.
0
0
.
0
n
/
a
2
.
2
1
.
3
0
.
8
1
.
6
2
.
0
2
.
7
2
.
9
2
.
6
0
.
9
t
y
p
e
g
e
n
.
s
p
.
1
8
a
m
u
c
.
7
3
.
8
1
.
6
2
.
2
1
.
1
0
.
5
4
.
0
4
.
1
2
.
4
5
.
2
2
.
1
4
.
0
3
.
8
4
.
2
1
.
1
1
6
9
7
.
1
0
.
5
1
.
1
0
.
0
0
.
0
7
.
8
7
.
8
2
.
0
1
1
.
7
5
.
8
*
*
*
*
7
.
8
4
.
3
1
0
.
4
2
.
4
*
*
*
*
*
*
*
3
3
9
4
.
1
2
.
1
4
.
3
0
.
0
0
.
0
4
.
3
5
.
1
3
.
7
6
.
0
1
.
6
3
.
9
4
.
0
3
.
8
0
.
9
5
2
9
1
.
1
0
.
0
0
.
0
0
.
0
n
/
a
1
.
2
0
.
8
1
.
2
0
.
5
0
.
4
1
.
4
2
.
1
0
.
9
0
.
4
5
8
9
4
.
1
1
.
1
1
.
1
1
.
1
1
.
0
4
.
4
6
.
2
6
.
5
6
.
0
0
.
9
3
.
3
3
.
8
2
.
9
0
.
8
*
*
*
*
2
a
c
u
t
.
4
4
.
1
1
.
1
1
.
1
1
.
1
1
.
0
4
.
5
3
.
1
1
.
2
4
.
4
3
.
6
*
5
.
3
6
.
4
4
.
5
0
.
7
*
5
7
4
2
.
7
1
.
1
2
.
2
0
.
0
0
.
0
2
.
9
2
.
3
0
.
8
3
.
3
4
.
0
3
.
2
4
.
3
2
.
4
0
.
6
3
2
6
.
0
8
.
6
7
.
6
9
.
5
1
.
2
5
.
7
7
.
2
6
.
9
7
.
4
1
.
1
4
.
8
3
.
8
5
.
5
1
.
5
1
0
2
6
.
0
3
.
2
2
.
2
4
.
2
1
.
9
6
.
3
4
.
1
3
.
7
4
.
4
1
.
2
7
.
7
6
.
0
9
.
0
1
.
5
*
*
7
7
2
6
.
7
2
.
1
0
.
0
4
.
2
n
/
a
7
.
3
6
.
4
4
.
1
7
.
9
1
.
9
7
.
8
6
.
9
8
.
5
1
.
2
*
a
n
y
a
c
u
t
.
1
7
.
1
1
1
.
2
9
.
8
1
2
.
6
1
.
3
1
7
.
8
1
6
.
0
1
3
.
0
1
8
.
0
1
.
4
1
8
.
8
1
8
.
3
1
9
.
2
1
.
0
4
9
b
3
9
.
2
1
.
1
2
.
2
0
.
0
0
.
0
1
0
.
1
5
.
9
6
.
5
5
.
5
0
.
8
1
2
.
7
1
3
.
3
1
2
.
3
0
.
9
*
*
*
*
*
*
7
6
3
4
.
0
1
.
6
2
.
2
1
.
1
0
.
5
4
.
3
1
.
5
1
.
6
1
.
4
0
.
8
6
.
0
7
.
1
5
.
2
0
.
7
*
*
*
*
7
5
3
5
.
0
1
.
1
1
.
1
1
.
1
1
.
0
5
.
5
2
.
6
2
.
4
2
.
7
1
.
1
7
.
2
9
.
8
5
.
4
0
.
5
*
*
*
*
*
*
3
8
2
7
.
6
0
.
5
1
.
1
0
.
0
0
.
0
8
.
4
4
.
6
4
.
1
4
.
9
1
.
2
1
0
.
8
1
2
.
1
9
.
9
0
.
8
*
*
*
*
*
*
2
3
2
3
.
5
0
.
5
1
.
1
0
.
0
0
.
0
3
.
8
2
.
0
1
.
6
2
.
2
1
.
3
4
.
9
6
.
2
4
.
0
0
.
6
*
*
9
2
7
.
1
2
.
7
4
.
3
1
.
1
0
.
2
7
.
6
5
.
1
4
.
5
5
.
5
1
.
2
9
.
2
1
1
.
4
7
.
6
0
.
7
*
*
*
1
7
2
7
.
0
2
.
7
1
.
1
4
.
2
3
.
9
7
.
5
3
.
9
3
.
7
4
.
1
1
.
1
9
.
7
1
1
.
0
8
.
8
0
.
8
*
*
*
*
Seroprevalence of 34 HPV Types in Germany
PLoS Pathogens | www.plospathogens.org 4 June 2008 | Volume 4 | Issue 6 | e1000091s
e
r
o
p
o
s
i
t
i
v
i
t
y
(
%
)
a
d
u
l
t
s
c
h
i
l
d
r
e
n
1
–
1
4
y
e
a
r
s
a
l
l
a
d
u
l
t
s
1
5
–
3
4
y
e
a
r
s
(
y
o
u
n
g
a
d
u
l
t
s
)
.
3
4
y
e
a
r
s
(
o
l
d
e
r
a
d
u
l
t
s
)
w
h
o
l
e
s
t
u
d
y
c
h
i
l
d
r
e
n
m
f
f
/
m
y
o
u
n
g
a
d
u
l
t
s
m
f
f
/
m
o
l
d
e
r
a
d
u
l
t
s
m
f
f
/
m
c
h
i
l
d
r
e
n
v
s
y
o
u
n
g
a
d
u
l
t
s
y
o
u
n
g
a
d
u
l
t
s
v
s
o
l
d
e
r
a
d
u
l
t
s
s
e
r
o
p
o
s
i
t
i
v
e
f
o
r
n
=
1
7
9
7
n
=
1
8
7
n
=
9
2
n
=
9
5
p
r
e
v
.
r
a
t
i
o
a
n
=
1
6
1
0
n
=
6
1
2
n
=
2
4
6
n
=
3
6
6
p
r
e
v
.
r
a
t
i
o
n
=
9
9
8
n
=
4
2
0
n
=
5
7
8
p
r
e
v
.
r
a
t
i
o
p
b
p
1
5
2
7
.
1
0
.
5
0
.
0
1
.
1
n
/
a
7
.
9
5
.
1
3
.
3
6
.
3
1
.
9
9
.
6
1
1
.
7
8
.
1
0
.
7
*
*
*
*
*
9
2
4
5
.
2
0
.
5
0
.
0
1
.
1
n
/
a
5
.
8
3
.
4
1
.
6
4
.
6
2
.
9
7
.
2
8
.
3
6
.
4
0
.
8
*
*
*
2
0
1
5
.
5
1
.
6
2
.
2
1
.
1
0
.
5
5
.
9
3
.
9
2
.
4
4
.
9
2
.
0
7
.
1
8
.
6
6
.
1
0
.
7
*
*
9
3
1
0
.
6
0
.
0
0
.
0
0
.
0
n
/
a
0
.
7
0
.
5
0
.
4
0
.
5
1
.
3
0
.
8
1
.
2
0
.
5
0
.
4
2
4
1
4
.
7
0
.
0
0
.
0
0
.
0
n
/
a
5
.
2
3
.
1
1
.
6
4
.
1
2
.
5
6
.
5
7
.
4
5
.
9
0
.
8
*
*
*
5
1
5
.
5
1
.
1
2
.
2
0
.
0
0
.
0
6
.
0
3
.
6
2
.
8
4
.
1
1
.
4
7
.
4
1
0
.
5
5
.
2
0
.
5
*
*
*
*
3
6
1
3
.
8
1
.
1
0
.
0
2
.
1
n
/
a
4
.
2
3
.
3
2
.
4
3
.
8
1
.
6
4
.
7
5
.
7
4
.
0
0
.
7
8
1
1
1
.
3
2
.
1
2
.
2
2
.
1
1
.
0
1
2
.
4
7
.
4
6
.
5
7
.
9
1
.
2
1
5
.
4
1
7
.
6
1
3
.
8
0
.
8
*
*
*
*
*
*
a
n
y
b
2
6
.
3
1
1
.
2
9
.
8
1
2
.
6
1
.
3
2
8
.
0
1
7
.
6
1
6
.
7
1
8
.
3
1
.
1
3
4
.
4
3
6
.
9
3
2
.
5
0
.
9
*
*
*
*
*
9
5
c
1
7
.
7
1
.
6
2
.
2
1
.
1
0
.
5
8
.
4
6
.
4
5
.
3
7
.
1
1
.
3
9
.
6
1
0
.
2
9
.
2
0
.
9
*
*
*
6
5
1
9
.
9
0
.
5
1
.
1
0
.
0
0
.
0
1
1
.
0
8
.
3
8
.
1
8
.
5
1
.
0
1
2
.
6
1
4
.
3
1
1
.
4
0
.
8
*
*
*
*
*
*
4
1
1
6
.
9
4
.
8
6
.
5
3
.
2
0
.
5
1
8
.
3
1
8
.
3
1
6
.
3
1
9
.
7
1
.
2
1
8
.
3
2
0
.
2
1
7
.
0
0
.
8
*
*
*
*
5
0
3
4
.
1
1
.
1
0
.
0
2
.
1
n
/
a
4
.
4
2
.
8
1
.
2
3
.
8
3
.
1
5
.
4
6
.
4
4
.
7
0
.
7
*
4
8
2
7
.
4
1
.
6
1
.
1
2
.
1
1
.
9
8
.
1
5
.
7
6
.
5
5
.
2
0
.
8
9
.
5
1
0
.
5
8
.
8
0
.
8
*
*
*
6
0
4
0
.
7
0
.
0
0
.
0
0
.
0
n
/
a
0
.
7
0
.
3
0
.
0
0
.
5
n
/
a
1
.
0
1
.
7
0
.
5
0
.
3
a
n
y
c
2
6
.
8
9
.
1
9
.
8
8
.
4
0
.
9
2
8
.
9
2
5
.
2
2
3
.
6
2
6
.
2
1
.
1
3
1
.
2
3
4
.
3
2
8
.
9
0
.
8
*
*
*
*
*
4
1
n
7
.
4
3
.
2
2
.
2
4
.
2
1
.
9
7
.
9
8
.
8
9
.
8
8
.
2
0
.
8
7
.
3
1
0
.
2
5
.
2
0
.
5
*
*
*
1
m
1
1
7
.
0
6
.
4
4
.
3
8
.
4
1
.
9
1
8
.
2
2
1
.
9
2
3
.
2
2
1
.
0
0
.
9
1
5
.
9
1
4
.
8
1
6
.
8
1
.
1
*
*
*
*
*
*
6
3
2
1
0
.
6
2
.
7
2
.
2
3
.
2
1
.
5
1
1
.
5
1
2
.
3
1
3
.
0
1
1
.
7
0
.
9
1
1
.
0
1
1
.
4
1
0
.
7
0
.
9
*
*
*
*
a
n
y
m
/
n
2
4
.
7
1
0
.
7
8
.
7
1
2
.
6
1
.
4
2
6
.
3
3
0
.
2
3
5
.
0
2
7
.
0
0
.
8
*
2
3
.
8
2
4
.
3
2
3
.
5
1
.
0
*
*
*
*
*
*
a
b
b
r
e
v
i
a
t
i
o
n
s
:
c
u
t
.
c
u
t
a
n
e
o
u
s
,
f
f
e
m
a
l
e
s
,
g
e
n
.
g
e
n
u
s
,
m
m
a
l
e
s
,
m
u
c
.
m
u
c
o
s
a
l
,
n
/
a
n
o
t
a
v
a
i
l
a
b
l
e
,
p
r
e
v
.
p
r
e
v
a
l
e
n
c
e
,
s
p
.
s
p
e
c
i
e
s
.
a
f
e
m
a
l
e
o
v
e
r
m
a
l
e
p
r
e
v
a
l
e
n
c
e
r
a
t
i
o
;
b
p
,
t
w
o
-
s
i
d
e
d
F
i
s
h
e
r
’
s
e
x
a
c
t
t
e
s
t
;
*
p
,
0
.
0
5
;
*
*
p
,
0
.
0
1
;
*
*
*
p
,
0
.
0
0
1
;
*
*
*
*
p
,
0
.
0
0
0
1
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
p
a
t
.
1
0
0
0
0
9
1
.
t
0
0
1
T
a
b
l
e
1
.
C
o
n
t
.
Seroprevalence of 34 HPV Types in Germany
PLoS Pathogens | www.plospathogens.org 5 June 2008 | Volume 4 | Issue 6 | e1000091Multiple HPV seropositivity
Antibody reactivity to more than one HPV type was frequent
(Table 1). While 24.5% of the sera (41.0% of the antibody
positives) were single positive, 11.5% reacted with two, 7.4% with
three and 16.2% with more than three HPV types. Even
seropositivities to more than 8 (6.1%) and more than 16 (1.9%)
types were observed. Multiple seropositivity (Figure 3), here
defined operationally as antibody positivity to at least half of the
HPV types analysed within a species or genus, followed in general
the patterns seen for type-specific seroprevalences (Figure 2).
Multiple seroreactions were rare in children (,15 years) and were
most prevalent in the second half of life (.34 years). Mucosal and
cutaneous a PV showed substantially less multiple seropositivity
than b, c, m and n types.
Multiple seropositvity to m and n PV showed a steep increase
already in young adults (15–24 years) and thus was the earliest to
occur in both genders. Multiple seropositivity to high-risk mucosal
a PV in women (but not in men) first occurred and also peaked at
25 to 34 years. For cutaneous a PV, multiple seropositivity showed
an isolated peak in the oldest age group in both genders. For b and
c PV, both genders showed two prevalence peaks, in women at
around 35 and 60 years and in men some 5 to 10 years later.
Discussion
Fundamental data on the humoral immune response to HPV
infections is scarce. Most serological analyses performed in the past
were case-control studies that mainly focussed on mucosal HR
HPV types highly prevalent in cervical cancer and mostly on
women at productive age. Little is known about the age
distribution of HPV infections, especially in children, men and
in old-aged individuals, and for many HPV types no serological
data is available at all. To understand the natural history of HPV
infections, investigations of a broad range of HPV types belonging
to different species and genera are needed. This is the first large
study to analyse simultaneously antibody reactions to 34 HPV
types in a general population. The cross-sectional data presented
here allow a detailed and comprehensive assessment of the
Figure 2. Prevalence of antibodies to 34 HPV types in the German population. Antibodies against HPV L1 proteins of 29 cutaneous and 5
mucosal HPV types were analysed in 1797 sera from the German general population and stratified by sex and age. The type-specific seroprevalences
in seven age groups are shown for females and males separately. Colour code, age groups in years and size of the groups are indicated in the inserts.
HPV types are specified below each graph, and genus, species, and tropism are shown between the graphs. Seroprevalence patterns were similar for
m and n PV, for high-risk mucosal a PV in females, and for b and c PV, respectively. Antibodies to cutaneous m and n PV were already present in
children with substantial prevalences in young adults (15–24 years). Antibodies to mucosal high-risk HPV appeared after puberty and peaked in the
25–34 years group mainly in women. Seroprevalence for b and c PV accumulated and peaked late in life in both genders. Most HPV showed two
seroprevalence peaks. Age at the first peak varied from about 20 to 50 years for the different genera, but the second prevalence peak rather
uniformly occurred at old age, in females at about 60 years and in males at above 64 years.
doi:10.1371/journal.ppat.1000091.g002
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type (and higher taxonomic order), sex and age. The data for the
children originating from two hospitalized groups may be less
representative for the German population. The conclusions of our
study results might also be limited due to the use of unadjusted
seroprevalence values. However, when age standardization was
applied seroprevalence estimates changed only marginally.
HPV of the same genus, with the exception of cutaneous a PV,
showed similar antibody patterns and are therefore discussed as
group. For comparisons with previously published prevalence data
across different laboratories it is important to keep in mind that
different assay formats and, probably even more important,
different cut-off definitions may greatly influence absolute
prevalence figures.
Genus m PV are associated with distinct common warts, HPV 1
with deep palmoplantar warts (myrmecia) and HPV 63 with cystic
or punctate, mainly plantar warts [6]. Warts [51,52] and especially
HPV 1 positive warts mostly occur at the age of 5 to 20 years
[6,28,29,53–55] while patients with HPV 63-induced warts were
10 to 39 years old [54,56]. HPV 41 of genus n originally isolated
from a facial wart of a 15 years old girl was found mainly in plane
hand warts but also in some skin carcinomas and actinic keratoses
[1,3,11,12].
In our study, seroprevalence for HPV 1 (17.0%) was the highest
among all types analysed, antibodies to HPV 63 (10.6%) were less
prevalent. These findings are in agreement with a study reporting
HPV 1 as the most prevalent type in warts from Germany (27.3%)
[57] and with other non-German studies reporting higher
prevalences in warts for HPV 1 (44.1% and 31.5%) than for
HPV 63 (0.9% and 16.4%), respectively [54,58]. Serological
studies using virus particles purified from warts as antigens also
frequently found antibodies to HPV 1 among mostly adults in 10%
[30] and 19.3% [20] of the control sera. However, HPV 1
antibody prevalences of 32% and higher in both patients with and
without a history of foot warts have been reported [28–34,36].
The substantial seroprevalence found in all studies indicates a high
frequency of infections with HPV 1 in the normal population. In
addition, HPV 1-induced warts contain high viral loads [53,59]
likely to result in more antigen presentation and thus in increased
antibody production.
In both sexes, antibodies against m and n PV were the first to be
seen. Seroprevalence peaked after the age of 14 and declined only
slightly thereafter. In line with this observation, Hamsikova et al.
[37] and Pfister et al. [28] reported a seroprevalence peak for HPV
1 at 13–30 years and 11–20 years, respectively. Two other studies
reported seroprevalence to peak in children younger than 15 years
[29,35]. Assuming no newly acquired foot wart in adults and thus
no new seroconversion, the data suggest a delayed but long lasting
antibody induction detectable even decades after the initial
infection.
In our study, type-specific seroprevalences for HR mucosal
HPV in adult women (.14 years) were highest for HPV 16
(10.9%) followed by HPV 33 (4.7%), 18 (4.6%), 58 (4.1%), and 52
(0.7%). DNA prevalences for HR types in German women
without cervical abnormalities were concordantly also highest for
HPV 16 (14.6%) followed by HPV 58 (2.7%), 52 (2.5%), 33
(2.2%), and 18 (1.7%) [60]. Another study on type-specific HPV
DNA prevalence in West German women also found HPV 16
(26.2%) as the most frequent type, followed by HPV 31 (10.1%),
18 (5.3%), 58 (4.5%), 33 and 52 (both ,4%) [61]. In adult men,
we found the highest seroprevalence for HPV 58 (4.8%),
inconsistent with DNA data identifying HPV 16 as the most
prevalent HR type in men [62].
Antibodies to HR mucosal a PV were rare in children (HPV 16
0.5%, other HR types 0.0–2.1%), which is consistent with
seroprevalence rates for HPV 16 in children ranging from 1.5–
7.6% reported by other studies [63]. In women, these antibodies
increased after puberty (reflecting the start of sexual activity) and
peaked at 25–34 years, whereas in men seroprevalence did not
increase strongly until the second half of life. This antibody
Figure 3. Multiple HPV seropositivity stratified by age and sex. Frequency of multiple seropositivity (seropositivity to at least half of the HPV
types analysed within a species or genus) in seven age groups are shown for females and males separately. Colour code, age groups in years and size
of the groups are specified in the inserts. Phylogenetic groups (genera and species) and their specific multiple seropositivity definitions (e.g.
seropositive for $8 out of 15 b PV types) are indicated. muc., mucosal; cut., cutaneous. Multiple seropositivity was lowest for mucosal and cutaneous
a PV and in general followed the patterns seen for type-specific seroprevalences (Fig. 2). For m and n PV, it was the earliest to occur in young adults of
both genders. For mucosal a PV, it was present mainly in women and peaked at 25–34 years. For cutaneous a PV, multiple seropositivity showed an
isolated peak in the oldest age group. For b and c PV, both genders showed two prevalence peaks, in women at around 35 and 60 years and in men
some 5 to 10 years later.
doi:10.1371/journal.ppat.1000091.g003
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studies [64–71] and is in agreement with a DNA prevalence peak
for mucosal (predominantly HR) HPV frequently found in women
younger than 30 years. With increasing age, HPV DNA
prevalence decreases [72–76], however a second peak in women
around 50 years [77] or 60 years and older [78–81] has been
reported. Consistently with the latter studies, we found a second
seroprevalence peak for HR HPV in women older than 45 years.
HPV 16 serology in comparison to the other HR HPV was
unique. Only for HPV 16, seroprevalence was significantly higher
in women than in men both among younger and older adults,
while seroprevalence for the other mucosal HR types showed only
a non-significant increase in women. Although studies on HPV
seroprevalence in men are rare, the lower seroprevalence for
mucosal HPV types 6, 11, and 16 assessed by virus-like particle
(VLP) serology is well known [66,71,82–89]. Several biological
and anatomical sex-dependent differences were discussed as
possible explanations: HPV infections of the penis involve rather
keratinized than mucosal epithelium which might be less
susceptible for the virus, less productive, and less accessible for
the immune system. Men might have rather transient infections
with lower viral loads that induce a weaker antibody response than
in women. Overall DNA prevalence of mucosal HPV types in
cytologically normal cervical smears ranges from 1.4% to 44%
[90,91]. In healthy men, overall HPV DNA prevalence values of
3.5% to 45% for mucosal types in exfoliated cells of the penis are
in the same range [62]. In view of this similar prevalence in penile
versus cervical samples, the assumption of lower susceptibility of
men cannot be held up.
It has been shown that persistent infection is associated with
higher seroprevalence [92,93]. Thus, HPV 16 might not only be
more prevalent in women compared with men but also more
persistent, with higher viral DNA loads, and with a greater
amount of intact virions. HPV 16 is the most prevalent HPV type
in low-grade squamous intraepithelial lesions [94], and these
lesions are known to express L1 [95]. In addition, HPV 16 is
possibly more immunogenic than other HR types [96,97].
The most heterogeneous antibody distribution with regard to
both age and type was seen for cutaneous a PV, although they are
closely sequence-related. However, due to the overall low
seroprevalence, the power of this pattern analysis is low. While
antibodies to HPV 3 were frequent in children and decreased with
age, seroprevalences for HPV types 2, 57, 10, and 77 were low in
children and increased with age. These findings may suggest
different natural histories of the individual wart-associated a PV
types. HPV 3 and 10 are associated with plane, HPV 2 and 57 with
common, and HPV 27 with intermediate warts [6]. HPV 77 has
been found in tumours and warts of immunosuppressed but not in
lesions of immunocompetent individuals [98]. HPV 2-associated
warts havebeenmost frequentlyfound inthe 20–40 years age group
[53,54,99], and in another study the prevalence of HPV 2/27/57-
induced warts peaked at the age of 21–25 years [55].
For b and c PV, age distribution patterns were very
homogeneous. Seroprevalence for these types was low in children
and increased with age. In middle-aged women, seroprevalence
tended to be higher than in men of the same age. In older adults,
this sex ratio shifted to a higher seroprevalence for men. We
observed two seroprevalence peaks, both occurring slightly earlier
in women than in men. At present, we can only speculate about
potential reasons for the sex-associated serological differences for b
and c PV. In men, body hair is more abundant, the use of
chemicals on the skin (cosmetics) is probably reduced, and for the
population studied here sun exposure for large parts of the body
during outdoor work might have been more frequent.
Serological studies showed elevated prevalences of antibodies to
b PV, mainly HPV 5 and 8, in EV and in immunosuppressed
patients, in patients with dermatological diseases like squamous
cell carcinoma of the skin [20,23–25,38–41] or psoriasis [21,24]
and in patients with second degree burns [20]. Feltkamp et al.
found a statistically significant association of seropositivity with age
and male sex for HPV 24 but not for HPV 5, 8, 15, 20 and 38 [38]
while in two other studies HPV 8 seropositivity was not correlated
with age and/or sex [23,24].
DNA prevalence data indicate an ubiquitous distribution of
these types in the population. Cutaneous HPV mainly of genus b
are found in normal skin and plucked hairs of different body sites
from healthy individuals, with up to 96% overall DNA prevalence
in adults [10,100,101]. In samples from different skin regions of an
individual, the same types are frequently found [100,102]. Type
patterns in plucked eye brow hairs and on healthy skin of an
individual frequently persist [101,103]. DNA from b and c PV has
been found in specimens taken with wet cotton-tipped swabs from
the foreskin of infants within days after birth [104] thus
demonstrating exposure. However, in the absence of additional
data showing active virus infection in the infant’s cells, it remains
unclear whether these findings show infection to occur early in life.
In adults, HPV DNA prevalence increases with age in both
genders [100,105]. We observed increasing seroprevalence in
females until around 40 and in males until around 50 years. This
suggests that seroconversion for HPV of these two genera in
contrast to m and n PV is extremely slow and occurs only years or
even decades after the initial infection. Alternatively, this might
indicate that despite early exposure active infection occurs much
later. DNA of these types in immunocompetent individuals is
present only in very low copy numbers [106]. A single contact with
these types might therefore not result in antibody induction.
However, accumulation of cutaneous HPV infections over lifetime
due to an increased exposure via intense skin contacts could lead
to higher overall viral loads and thus to an increasing
seroprevalence with age. In addition, the weakening of the
immune system in older age and/or perhaps increased sun-
exposure might be responsible for the inability to control viral
replication which consequently leads to higher viral loads and
higher seroprevalences.
For most of the analysed HPV types, seroprevalence peaked
twice. A possible explanation for the second peak at ages beyond
55 years is a reactivation of latent infections perhaps by reduction
of immune surveillance with increasing age followed by increasing
viral load and antibody induction. For mucosal a PV in women, it
might in addition be caused by changes in the genital epithelium
associated with menopause. Alternatively, the seroprevalence in
older age groups of this serum collection might be due to a cohort
effect. Possibly varying behaviour in different birth cohorts might
have influenced exposure, such as sexual behaviour for genital
HPV. We speculate that also environmental factors, such as sun
exposure or nutrition, may have influenced the extent of HPV
replication and/or the functionality of the immune system. The
sera of this study were collected in 1987 and 1988. It remains to be
examined whether this age-dependent distribution will also be
present in sera collected 20 years later.
We observed a substantial frequency of multiple seropositive
reactions, e.g. 48% of HPV 5 positive sera reacted also with HPV
8. Multiple infections with mucosal HPV [62,91] and even more
often with cutaneous HPV both in immunosuppressed as well as
immunocompetent individuals are common [100,107]. Multiple
seropositivity may result from type-specific reactions to multiple
infections and/or could be due to cross-reactive antibodies
induced by an infection with only one or few HPV types. The
Seroprevalence of 34 HPV Types in Germany
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two possibilities. To address this issue, we investigated i) whether
double seropositivity for a given pair of HPV types was observed
more often than expected by chance and ii) whether double
seropositivity was correlated with sequence identity of the
respective L1 proteins (shown in supplementary material Figure
S1 and Text S1). If multiple seropositivity was due to cross-
reactivity, it should be explainable by the degree of relatedness of
HPV types. Our results showed that multiple seropositivity was not
or only weakly correlated with L1 amino acid sequence
relatedness, and thus we consider the measured antibodies to be
mainly type-specific. However, cross-reactivity can only be
appropriately investigated by means of absorption experiments
or monospecific antisera which are currently not available for most
HPV types.
One limitation of this study is the use of a uniform, arbitrarily
defined cut-off for seroprevalence calculations. For assays of
antibodies to sexually transmitted genital HPV, cut-off definitions
can be based on seroreactivities in groups of virgins [108] while for
the cutaneous types representing the vast majority of HPV types
analysed here the definition of a mostly uninfected and thus mostly
seronegative group is not possible. In the absence of defined
reference sera that could be used as international standards, any
cut-off definition has an arbitrary component and seroprevalence
values obtained by different laboratories in general should only be
compared with caution.
In our study all antigens were identically constructed L1 fusion
proteins expressed in the same bacterial expression system. The
full-length L1 fusion protein density on the beads for different
HPV types was very similar, since MFI values obtained after
staining of the carboxy (C)-terminal tag epitope with a monoclonal
antibody varied less than two-fold. Thus, given the similar
properties of the antigens the use of an uniform cut-off appears
justified. To avoid false-positivity by low-level cross-reactivity and
to increase type specificity of the seroprevalence values, a cut-off
well above background levels was chosen. Thus, the cut-off is
rather stringent and probably underestimates the true seroprev-
alence of cutaneous HPV infections.
However, as shown in Figure 1, the major conclusions are
independent of the chosen cut-off. The age-dependent distribution
of skin HPV antibodies as well as the unique pattern of HPV 16
antibodies in women are also present at very low seroreactivity
levels (MFI values well below the chosen cut-off).
Direct comparison of GST-L1 fusion protein- and VLP-based
ELISA with human sera has been performed for HPV 16 and 18,
and showed good correlation [48,50]. Of 46 monospecific
monoclonal antibodies detecting conformational epitopes on
VLP of 9 mucosal types of which 4 (HPV 16, 18, 33, and 52)
are also used here all reacted with the GST-L1 fusion protein of
the same type [50] demonstrating the ability of GST-L1 to bind
type-specific antibodies. Based on these observations, it is
reasonable to assume similar properties for the other 30 HPV
types investigated here. We cannot entirely exclude cross-reactivity
and thus unspecific antibody reactions. Like VLP, GST fusion
proteins present conformational and neutralising epitopes but
display a higher amount of linear/cross-reacting epitopes than
VLP [50]. Thus, under the condition that only highly purified,
intact VLP preparations are used as antigens, VLP-based assays
may yield a higher ratio of specific to unspecific reactions than
with GST-L1-based serology.
In conclusion, the serological results presented here suggest
different seroprevalence patterns of phylogenetically related HPV:
Antibodies to cutaneous m and n PV appear late in childhood,
those to mucosal high-risk HPV after puberty mainly in women,
and seroprevalence for b and c PV peaked late in life in both
genders.
The assays developed here allow further serological investiga-
tions to enlarge our still scarce knowledge on the natural history of
especially cutaneous HPV infections. Interesting issues are e.g.
effect of sun exposure on HPV prevalence, and the immune
response in EV patients and patients with cutaneous warts in
comparison to healthy people. In addition, seroepidemiological
case-control studies might help to understand the potential role of
cutaneous HPV in the development of non-melanoma skin cancer.
Materials and Methods
Recombinant HPV L1 proteins
HPV L1 open reading frames were expressed via the pGEX4T3
vector (GE Healthcare, Mu ¨nchen, Germany) in E.coli Rosetta cells
(Merck, Darmstadt, Germany) as double fusion proteins with
amino (N)-terminal GST and a C-terminal peptide (tag) consisting
of the last 11 amino acids from the large T antigen of simian virus
40. The expression constructs for the L1 proteins of HPV types 16
and 18 have been described [48]. Constructs for full-length L1 of
HPV types 1a, 2a, 3, 4, 5, 8, 9, 10, 15, 17, 20, 23, 24, 33, 36, 38,
41, 48, 49, 50, 52, 57, 58, 60, 63, 65, 75, 76, 77, 92, 93, and 95
were generated in the same fashion. HPV genomes used as PCR
templates, amplified regions, and cloning enzymes are listed in
Table 2. HPV sequences were verified by commercial sequence
analyses and aligned by HUSAR (Heidelberg Unix Sequence
Analysis Resources, http://genome.dkfz-heidelberg.de/). Se-
quences of 27 of the 34 L1 constructs were identical with the
published HPV nucleotide sequence. Seven of the 11 sequence
variations in L1 of HPV 5, 8, 10, 16, 18, 41, and 57 resulted in
amino acid changes (Table 2). Eight of the mismatches were
present already in the parental plasmids, indicating possibly
mistakes in the published sequences. Of the three PCR-generated
mismatches, only one lead to a threonine (T) to serine (S) amino
acid change in HPV 10 L1. This error was not corrected since T
and S are functionally very similar amino acids. The sequence of
the parental HPV 5 L1 ORF used here [109,110] was newly
determined and submitted to GenBank (AM922325). In compar-
ison to the most closely related published HPV 5 sequence (HPV
5b [111], D90252), it showed 17 mismatches and a 27 nucleotide
deletion (2.9% sequence variation) and therefore probably
represents a new subtype.
Fusion protein expression was induced at room temperature by
0.25 mM isopropyl-b-D-thiogalactoside (IPTG) and six h after
induction bacteria were harvested. The pellet from a 1 liter culture
was resuspended in 10 mL of 40 mM Tris, 200 mM NaCl, 1 mM
EDTA, pH 8.0, 2 mM DTT containing complete protease
inhibitor cocktail (Roche, Mannheim, Germany), and lysed with
a high pressure homogenizer (Avestin, Ottawa, Canada). After
incubation with 2 mM ATP and 5 mM MgCl2 for 1 h at room
temperature, lysates were cleared from insoluble components (e.g.
cell membranes) by centrifugation (14,000 rpm, 4uC, 30 min). For
all HPV types, the proportion of insoluble fusion protein was low.
Supernatants were stored with 50% glycerol at 220uC.
Fusion protein expression was characterised by Coomassie-
stained sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) as described [49]. Western blot analyses using GST
and tag specific antibodies showed full-length fusion proteins of
approximately 84 kDa and some additional minor bands of
shorter fragments. N-terminal (GST-reactive) fragments were
more prevalent than C-terminal (tag-reactive) fragments indicating
incomplete translation rather than proteolysis as cause for the
smaller fragments (data not shown).
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proteins in the lysates was determined by GST-capture ELISA
[49] using a tag-specific antibody for fusion protein detection. For
all constructs, glutathione-casein saturation with fusion protein
was reached with 200 mg total lysate protein/mL or less. Half
maximal binding ranged from 16.5 mg/mL (HPV 3 L1) to 0.3 mg/
mL (HPV 48 L1) (median 2.6 mg/mL) indicating about 55-fold
variation in GST-L1-tag concentrations in the lysates.
Human sera
Anonymous sera from 1797 individuals (age 1–82 years, median
37 years; 758 males and 1039 females) were analysed. These sera
originated from three serum collections. The largest contribution is
from the population-based German Nutrition Survey (Nationale
Verzehrstudie NVS, [112,113]) collected in the German popula-
tion aged 4–94 years between October 1985 and January 1989
(n=23,209). The VERA study (Verbundstudie Erna ¨hrungserhe-
bung und Risikofaktorenanalytik) is a random subsample of the
NVS population aged 18 years and older collected in 1987 and
1988 (n=1988) [112,113]. We tested the available 1573 (79.1%)
VERA serum samples (age 18–82 years, median 41 years; 651
males and 922 females). Sera from children (below 19 years) were
obtained from two other collections: (i) 175 sera from children (age
2–18 years, median 9 years; 71 males and 104 females) treated in
2002 at the university hospital in Homburg (Germany) were
randomly selected from a collection of stored diagnostic sera and
(ii) 49 sera (age 1–10 years, median 5 years; 36 boys and 13 girls)
collected for a previous HPV serology study [114] in 1991 and
1992 from children treated at the university hospital in Heidelberg
(Germany).
The age structure of the tested VERA samples is indifferent
from the age structure of the NVS population aged 18 years and
older (p=0.9808), and the age structure of our total study (1573
sera from VERA, 175 children sera from Homburg, and 49
children sera from Heidelberg, total n=1797) is characteristic for
the age structure of the total NVS population (p=0.9629). This
allows the conclusion that our study is likely to be representative of
the German population.
Multiplex serology
Sera were analysed simultaneously for antibodies to 34 HPV
types by multiplex serology as described [46,47]. Briefly, GST-L1-
tag fusion proteins from cleared lysates were affinity-purified in situ
through binding to the glutathione casein-coated fluorescence-
labelled polystyrene beads. Each fusion protein was bound to a
spectrally distinct bead set. A total lysate protein concentration of
1 mg/mL was used for all lysates, an at least five-fold excess to
saturate GST fusion protein binding on the beads. Monoclonal
anti-tag antibody binding to the different antigen-loaded bead sets
varied less than two-fold, indicating similar full-length L1 fusion
protein density for the different HPV types. Fusion protein-loaded
bead sets were mixed. Sera were pre-incubated at 1:50 dilution in
PBS containing 1 mg/mL casein, 2 mg/mL lysate from bacteria
expressing GST-tag alone to block antibodies directed against
residual bacterial proteins and GST-tag, 0.5% polyvinylalcohol
(PVA, Sigma-Aldrich), 0.8% polyvinylpyrrolidone (PVP, Sigma-
Aldrich) and 2.5% Superchemiblock (Millipore, Billerica, MA,
USA) to suppress unspecific binding of antibodies to the beads
themselves [47]. Serum dilutions were incubated with the same
volume of mixed bead sets, resulting in a final serum dilution of
1:100. Bound antibodies were detected with biotinylated goat-anti-
human IgG (H+L) secondary antibody and streptavidin-R-
phycoerythrin. A Luminex analyser (xMAP, Luminex Corp.,
Austin, Texas, USA) was used to identify the internal colour of the
individual beads and to quantify their reporter fluorescence
(expressed as median fluorescence intensity (MFI) of at least 100
beads per set per serum). A fusion protein consisting of GST and
Table 2. Characteristics of expressed HPV L1 sequences.
HPV
type
Accession
number
a
Amplified region/
cloning enzymes
b Mismatches
c
1a V01116 B-5431-6936-S
2a X55964 Sm-5742-7271-S
3 X74462 B-5751-7262-S
4 X70827 B-5345-6892-S
5 AM922325 B-1-1551-S G1533A
d,e
8 M12737 B-5851-7392-S A7383G
d,e
9 X74464 B-5745-7265-S
10 X74465 E-5823-7331-S C7324G (T to S)
d
15 X74468 B-5703-7223-S
16R
f,g not yet entered
h Sm-5669-7153-S A6434G (T to A)
i
17 X74469 B-5724-7244-S
18
f,g X05015 Sm-5643-7133-S C5701G (P to R)
i,
C6460G (P to R)
i,
C6625G (P to R)
i,
C6842G
e,i
20 U31778 B-5893-7440-S
23 U31781 Sm-5660-7177-S
24 U31782 B-5713-7248-S
33 M12732 B-5594-7090-S
36 U31785 Sm-5891-7438-S
38 U31787 Sm-5661-7190-S
41 X56147 E-5546-7084-S T5905C
e,i, G6165C (S to T)
i
48 U31789 E5202-6740-S
49 X74480 B-5811-7337-S
50 U31790 E-5231-6775-S
52 X74481 B-5643-7151-S
57 X55965 B-5751-7232-S T6180A (Y to N)
i
58 D90400 B-5643-7136-S
60 U31792 E-5395-6918-S
63 X70828 E-5371-6891-S
65 X70829 B-5326-6873-S
75 Y15173 B-5771-7297-S
76 Y15174 Sm-5799-7325-S
77 Y15175 B-5789-7297-S
92 AF531420 B-5638-7173-S
93 AY382778 B-5640-7178-S
95 AJ620210 B-5368-6912-S
asource of genome sequences: GenBank.
bB=BamHI, E=EcoRI, S=SalI, Sm=SmaI; first and last HPV nucleotide.
cnucleotide changes and positions, amino acid changes are indicated in
brackets.
dPCR-generated mutation.
esilent mutation.
fdescribed in Sehr et al. 2002 [48].
gL1 lacks 10 N-terminal amino acids.
hftp://ftp-t10.lanl.gov/pub/papilloma/GenBank-files/Human-papilloma/
HPV16R.gb.
imutations present in parental HPV plasmid.
doi:10.1371/journal.ppat.1000091.t002
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determination.
Assay design and data processing
The glutathione-casein coupled bead sets were loaded with their
respective antigen in one batch. The efficiency of antigen loading
on beads was quantified via the C-terminal tag as described [46].
Values (mean MFI of 3 wells) for the different antigens ranged
from 4604 (HPV 58 L1) to 9065 (HPV 95 L1) with a median of
6180 MFI. Correct antigen loading was verified with 25 reference
sera with known HPV antibody pattern. These sera originated
from two earlier studies analysing the antibody reactivity to 16
[39] and 31 HPV types [45] by multiplex serology. All types
except HPV 33, 52, 58, and 60 were represented in the reference
sera.
Study sera were analysed once on three consecutive days. A
quality control panel (QC) of 46 sera was included each day
resulting in three QC data sets to determine inter-day variation.
For inter-day variations of raw MFI values, Pearson correlation
coefficients (R
2) for the individual antigens ranged from 0.761 to
0.986 (median 0.963) for day 2 versus 1 and from 0.691 to 0.989
(median 0.947) for day 3 versus 1. The raw data of days 2 and 3 for
each antigen were divided by the slopes of the regression lines of
the QC data pairs of days 1 and 2 or days 1 and 3, respectively, to
correct for inter-day variation.
The QC sera were also pooled and included as positive standard
on each plate. Inter-plate variation coefficients (CV) calculated
from these data for the various antigens ranged from 13.0% to
23.4% with a median of 16.6%.
Auto-fluorescence of each bead set and background reactions
resulting from binding of secondary reagents to the antigen-loaded
beads were determined in one well per plate without human
serum. After correction for inter-day variation, mean background
values (range 4 to 27 MFI, except for unusually high bead
backgrounds of 150 and 350 MFI for HPV 4 L1 and HPV 33 L1,
respectively) were subtracted from the raw MFI values and then
antigen-specific reactivity was determined by subtraction of the
MFI of GST-tag from the MFI of the specific antigen. Cut-off
values to define seropositivity for all antigens were arbitrarily set to
200 MFI.
Statistical analysis
Serological data were stratified by sex and age. Since sexual
transmission is known to play a major role in mucosal HPV
infection, the first age group encompassed children (14 years and
younger), followed by age groups in 10 year intervals. The age
distribution of our study and the German standard population as
reported by [115] is similar (p=0.695), and we present data
stratified by age. Age standardization was applied but changed
seroprevalence estimates only marginally. Therefore, unadjusted
seroprevalences are reported throughout this manuscript. Statis-
tical significance of differences in seroprevalence was assessed by
two-sided Fisher’s exact test. P-values below 0.05 were considered
statistically significant.
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